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Box-Behnken designAbstract The aim of the present work is to use experimental design to screen and optimize exper-
imental variables for developing a spectrophotometric method for determining ceﬁxime trihydrate
content using ninhydrin as a derivatizing reagent. The method is based on the reaction of the amino
group of ceﬁxime with ninhydrin in an alkaline medium to form a yellow-colored derivative (kmax
436 nm). A two-level full factorial design was utilized to screen the effect of ninhydrin reagent con-
centration (X1), volume of ninhydrin reagent (X2), heating temperature (X3) and heating time (X4)
on the formation of the ceﬁxime–ninhydrin complex Y (absorbance). One way ANOVA and Pareto
ranking analyses have shown that the ninhydrin reagent concentration (X1), volume of ninhydrin
reagent (X2) and heating temperature (X3) were statistically signiﬁcant factors (P< 0.05) affecting
the formation of the ceﬁxime–ninhydrin complex Y (absorbance). A Box-Behnken experimental
design with response surface methodology was then utilized to evaluate the main, interaction and
quadratic effects of these three factors on the selected response. With the help of a response surface
plot and contour plot the optimum values of the selected factors were determined and used for fur-
ther experiments. These values were a ninhydrin reagent concentration (X1) of 0.2% w/v, volume of
ninhydrin reagent (X2) of 1 mL and heating temperature (X3) of 80 C. The proposed method was
validated according to the ICH Q2 (R1) method validation guidelines. The results of the present
Figure 1 Structur
S102 Y.B. Wani, D.D. Patilstudy have clearly shown that an experimental design concept may be effectively applied to the
optimization of a spectrophotometric method for estimating the ceﬁxime trihydrate content in bulk
and pharmaceutical formulation with the least number of experimental runs possible.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ceﬁxime trihydrate (CEF) is an oral third generation cephalo-
sporin antibiotic used in the treatment of gonorrhea, tonsillitis
and pharyngitis [1]. Chemically, CEF is (6R, 7R)-7-{(2-(2-ami-
no-1, 3-thiazol-4-yl)-2-(carboxymethoxyimino) acetyl) amino}-
3-ethenyl-8-oxo-5-thia-1-azabicyclo (4.2.0) oct-2-ene-2-carbox-
ylic acid (Fig. 1) [2].
Two-level full and fractional factorial designs as well as
Plackett–Burman designs are used to screen the important fac-
tors that inﬂuence process output measures or product quality
[3]. A two-level full factorial design consists of two levels of
each experimental factor and has a design matrix made up of
all combinations of these factor levels. It can provide the direc-
tion for further experimentation [3].
Response surface methodology (RSM) is a statistical tech-
nique used for the development and optimization of complex
processes [4–6]. RSM is used after preliminary screening of
experimental factors that signiﬁcantly affect the response using
factorial designs [4]. The technique has several advantages over
conventional optimization method in which one variable is
used at a time (OVAT). RSM provides a large amount of
information and is a relatively economical approach because
a small number of experiments are performed for monitoring
the interaction of the independent variables and the response.
In conventional optimization, the increase in the number of
experiments necessary to carry out the research, leads to an in-
crease in time and expenses as well as an increase in the utili-
zation of reagents and materials for experiments [7].
Many types of response surface designs are used for optimi-
zation, such as central composite, Doehlert and Box-Behnken
designs. The Box-Behnken design is preferable to central com-
posite and Doehlert designs because it requires fewer test runs
and is rotatable. A design is rotatable only when the experi-
ments are roughly situated on a (hyper) sphere. By selection
of an adequate number of center points, it is possible to modify
the precision of the response of a predicted design to be similar
over the whole domain. Such a design is said to have uniform
precision [3].
The Box-Behnken design is advantageous because it does
not contain any points at the extremes of the cubic region cre-
ated by the two-level factorial combinations [4,5,8]. The Box-
Behnken design was selected in the present investigation and
used to optimize, validate and analyze CEF spectrophotomet-
rically, because the design provides three levels for each factor
and requires fewer runs in the three-factor case compared with
the central composite and Doehlert design.e of CEF.Numerous studies have been carried out on CEF. Indian
Pharmacopoeia [2], British Pharmacopoeia [9], United States
Pharmacopoeia [10] and European Pharmacopoeia [11] de-
scribed a liquid chromatographic method for estimating the
CEF content in bulk form and performing assays of oral suspen-
sions and tablet formulations of CEF. The use of spectropho-
tometry [12–18], spectroﬂuorimetry [17], high performance
liquid chromatography (HPLC) [12,19] and voltammetry [20]
to estimate the content of CEF in single-component formula-
tions was reported in the literature. Estimation of the content
of CEF in multicomponent formulations by spectrophotometry
[21–23], HPLC [24–27] and high performance thin layer chro-
matography (HPTLC) [28,29] was described in the literature.
The visible spectrophotometric method described by [12]
was based on the oxidative coupling reaction of CEF with 3-
methyl-2-benzothiazolinon hydrazone hydrochloride in the
presence of ferric chloride. [16] developed a stable, product
with a concentration dependent cherry-red color after the reac-
tion of CEF with sodium nitrite in an acidic solution. A spec-
trophotometric method based on the acidic oxidation of CEF
with cerium at elevated heating temperature was studied by
[17] and [18] described a spectrophotometric method in which
cephalosporins are converted into hydroxamic acid, which
forms a colored complex with iron(III). A simple, accurate
and precise spectrophotometric method based on the derivati-
zation of CEF with sodium 1,2-naphthoquinone-4-sulfonate
was developed by [30]. An accurate, precise and eco-friendly
spectrophotometric method for estimating the content of
CEF using ninhydrin was developed by [31]. The conventional
experimental method was utilized to optimize the reaction
variables in the above spectrophotometric methods. The one
variable at a time method is inefﬁcient and gives misleading re-
sults [7]. So it must be avoided. Therefore, there is a need to
use a systematic and statistical way of optimizing the reaction
variables so as to obtain signiﬁcant and precise results.
The aim of the present work was to utilize the experimental
design approach for screening and optimizing the experimental
variables for developing a spectrophotometric method for
determining the content of CEF in bulk and pharmaceutical
formulations using ninhydrin as a derivatizing reagent.
2. Experimental
2.1. Instrument
A Shimadzu UV–visible spectrophotometer 1700 (UV probe
software) with 1-cm matched quartz cells was used for measur-
ing the absorbance.
2.2. Materials
CEF was obtained as a gift sample from Centurion Laborato-
ries, Vadodara (Gujarat). HIFEN DT 100 tablets (100 mg)
Table 2 Experiment 24 and response value.
Standard Order Run Order X1 X2 X3 X4 Y
12 1 0.3 0.5 90 30 0.181
15 2 0.3 1.5 90 20 0.194
14 3 0.3 1.5 70 30 0.179
3 4 0.1 0.5 90 20 0.178
4 5 0.1 0.5 90 30 0.178
5 6 0.1 1.5 70 20 0.177
16 7 0.3 1.5 90 30 0.195
11 8 0.3 0.5 90 20 0.194
1 9 0.1 0.5 70 20 0.163
10 10 0.3 0.5 70 30 0.176
9 11 0.3 0.5 70 20 0.167
6 12 0.1 1.5 70 30 0.176
7 13 0.1 1.5 90 20 0.191
8 14 0.1 1.5 90 30 0.191
13 15 0.3 1.5 70 20 0.180
2 16 0.1 0.5 70 30 0.163
An experimental design approach for optimizationof spectrophotometric method S103and ZIFI DT 50 tablets (50 mg) were purchased from a local
medical shop. Analytical grade chemicals (ninhydrin reagent,
boric acid, potassium chloride, potassium dihydrogen phos-
phate, sodium hydroxide), HPLC grade methanol and distilled
water were used in the experiments. A Qualisil BDS C8 column
(250 · 4.6 mm, 5 lm)was used as the stationary phase inHPLC.
2.3. Reagents and standards
Ninhydrin reagent solutions (0.1% w/v, 0.2% w/v and 0.3%
w/v) were prepared in methanol. Alkaline borate buffer (pH
10) was prepared according to the procedure described in In-
dian Pharmacopoeia [2].
2.4. Standard solution for spectrophotometric method
A stock solution of CEF (1000 lg/mL) was prepared by dis-
solving 10.0 mg of CEF in 10.0 mL of a methanol: water mix-
ture (3:2, v/v).
2.5. Sample solution for spectrophotometric method
Twenty tablets of each brand were weighed and powdered. A
quantity of powder equivalent to 10.0 mg of CEF was trans-
ferred to a 10.0 mL volumetric ﬂask. Then, 5.0 mL of a meth-
anol: water mixture (3:2, v/v) was added to dissolve the
powdered drug. The mixture was sonicated in an ultrasonic
bath for 10 min, mixed and diluted up to the mark with the
same solvent. The solution was ﬁltered using a ﬁlter paper.
2.6. Standard solution for HPLC method
A stock solution of CEF (1000 lg/mL) was prepared by dis-
solving 10.0 mg of CEF in 10.0 mL of methanol. About
0.1 mL of stock solution (1000 lg/mL) was transferred to a
10.0 mL volumetric ﬂask and the ﬁnal dilution was made with
a diluent to obtain a 10 lg/mL solution of CEF.
2.7. Sample solution for HPLC method
Twenty tablets of each brand were weighed and powdered. A
quantity of powder equivalent to 10 mg of CEF was dissolved
inmethanol in a 10.0 mL volumetric ﬂask. Themixture was son-
icated for 20 min. The solution was ﬁltered using a 0.45 lm
membrane ﬁlter paper. About 0.1 mL of this solution was trans-
ferred to a 10.0 mL volumetric ﬂask. The ﬁnal dilution was car-
ried out with a diluent to obtain a 10 lg/mL solution of CEF.Table 1 Experimental factors and response variable for two level f
Experimental factors
Ninhydrin reagent concentration (% w/v)




Formation of ceﬁxime-ninhydrin complex (absorbance)2.8. Mobile phase
The mobile phase used for HPLC analysis was prepared by
mixing methanol and 0.025 M potassium dihydrogen phos-
phate in the proportion 70:30, v/v. The mobile phase was used
as a diluent for HPLC analysis.3. Methods
3.1. Two-level full factorial design
A two-level full factorial design was employed to evaluate the
effects of four independent factors, namely ninhydrin reagent
concentration (X1), volume of ninhydrin reagent (X2), heating
temperature (X3) and heating time (X4) on absorbance Y. On
the basis of preliminary experiments the ranges of values used
in the design are the following: ninhydrin reagent concentra-
tion (X1): 0.1–0.3% w/v; volume of ninhydrin reagent (X2):
0.5–1.5 mL; heating temperature (X3): 70–90 C and heating
time (X4): 20–30 min. The different levels of the selected fac-
tors are presented in Table 1 and the design matrix of the
two-level full factorial design is provided in Table 2. All the
experimental runs were performed in triplicate and results









Figure 2 UV–Visible spectrum of CEF-Ninhydrin complex.
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A three-level Box-Behnken design with three center points
(Table 3) was used to evaluate the main, interaction and qua-
dratic effects of ninhydrin reagent concentration (X1), volume
of ninhydrin reagent (X2) and heating temperature (X3) on
absorbance Y. The experimental conditions that were main-
tained constant include the alkaline borate buffer (pH 10,
1 mL), heating time (X4) (25 min) and the diluting solvent
(water). All the experimental runs were performed in triplicate
and the results are presented in Table 3.
3.3. Linearity study
An aliquot of the standard stock solution (0.05–0.3 mL) was
transferred to a 10.0 mL volumetric ﬂask. The total volume of
each ﬂask was brought to 1.0 mL with a methanol: water mix-
ture (3: 2 v/v). One milliliter of ninhydrin solution and 1.0 mL
of alkaline borate buffer solution (pH 10) were added to each
ﬂask. The reaction mixture was heated on a water bath at
80 C for 25 min. Then the reaction mixture was cooled to room
temperature. The ﬁnal volume was made up to 10.0 mL with
water. The yellow-colored reaction solution was scanned in
the range of 400–800 nm against a reagent blank. The wave-
length 436 nmwas selected as kmax for solution analysis (Fig. 2).
3.4. Assay of CEF in pharmaceutical formulation
Aliquots of about 0.1 and 0.2 mL of the standard stock and
sample solutions were transferred to 10.0 mL volumetric
ﬂasks, and the total volume was brought to 1.0 mL with a
methanol: water mixture (3:2, v/v). One milliliter of ninhydrin
solution and 1.0 mL of alkaline borate buffer solution (pH 10)
were added to each ﬂask. The reaction mixture was heated on a
water bath at 80 C for 25 min. Then the reaction mixture was
cooled to room temperature. The ﬁnal volume was made up to
10.0 mL with distilled water. The absorbance of standard and
sample solutions was measured at 436 nm. The content of CEF





AS WSamTable 3 Optimization method parameters for Box-Behnken experim
Run Pattern (X1, X2, X3) X1 X2
1 0 0.1 0.5
2 +0 0.1 1.5
3 000 0.2 1.0
4 +0+ 0.3 1.0
5 0+ 0.2 0.5
6 000 0.2 1.0
7 ++0 0.3 1.5
8 0 0.2 0.5
9 0 0.1 1.0
10 +0 0.3 0.5
11 +0 0.3 1.0
12 0++ 0.2 1.5
13 0+ 0.2 1.5
14 000 0.2 1.0
15 0+ 0.1 1.0%Labeled Claim ¼ XEst
XLC
 100
where, XEst = content of CEF per tablet of average weight;
AU = absorbance of the sample solution; AS = absorbance
of the standard solution; WStd = weight of the standard
(mg); WSam = weight of the sample (mg); WAvg = average
weight of a tablet (mg); and WLC = labeled content of CEF
per tablet (mg).
3.5. Assay of CEF in pharmaceutical formulation using the
reported HPLC method
The proposed method was statistically compared with the
HPLC method described previously by [26]. The prepared
standard and sample solutions were injected for HPLC analy-
sis. The mobile phase was pumped at a ﬂow rate of 1 mL/min.
The detection wavelength was set at 290 nm. A chromatogramental design.
















An experimental design approach for optimizationof spectrophotometric method S105was recorded for CEF. This shows a retention time of
2.74 min. Calculations were performed using the peak areas
of the standard and sample.
4. Results and discussion
A spectrophotometric method was optimized for determining
the content of CEF using ninhydrin as a derivatizing reagent.
The experimental design approach was utilized for screening
and optimizing the experimental variables of the spectrophoto-
metric method.
4.1. Two-level full factorial design
Screening designs are normally used when a large number of
factors are likely to affect a particular response [3]. A two-level
full factorial design was utilized to evaluate the main effect of
four independent factors on the selected response Y. The pri-
mary purpose was to identify signiﬁcant main effects with
the least number of runs as possible.
The effects of all the factors included in the experimental
design on the selected response Y are shown in Table 2. An ef-
fect was considered strong at P 6 0.05. The identiﬁed factor
was then considered as an inﬂuencing factor (IF). The effect
of each factor was interpreted as the average change in re-
sponse Y as the factor changed from a low to a high level (Ta-
ble 1). Pareto ranking analysis revealed that, the factors that
were statistically signiﬁcant (P< 0.05) for selected response
Y were the ninhydrin reagent concentration (X1), volume of
ninhydrin reagent (X2) and heating temperature (X3). The Par-
eto charts (Fig. 3) were derived from multivariate regression
analyses, and the length of each bar in the Pareto chart is
equivalent to the magnitude of the regression coefﬁcient of
that factor. The direction of the bar indicates whether the fac-
tor has a direct or inverse effect on the response. The ninhydrin
reagent concentration (X1), volume of ninhydrin reagent (X2)
and heating temperature (X3) have direct relationships with
the absorbance Y, and their effects are statistically signiﬁcant
(P< 0.05). The heating time (X4) also has a direct effect onFigure 3 Pareto chthe selected response Y but this is not statistically signiﬁcant
(P> 0.05).
4.2. Box-Behnken experimental design
Using multivariate regression analysis, a ﬁtted full quadratic
model was obtained for the average response Y, given by the
following equation:Y ¼ b0 þ b1X1þ b2X2 þ b3X3 þ b11X21 þ b22X22 þ b33X23
þ b12X1X2 þ b13X1X3 þ b23X2X3
where, Y = selected response; b0 = arithmetic mean response;
and b1, b2 and b3 = regression coefﬁcients of the factors X1,
X2 and X3, respectively.
Tables 4 and 5 have shown the values of regression coef-
ﬁcients and their associated P-values. It may be observed
that the ninhydrin reagent concentration (X1), volume of nin-
hydrin reagent (X2) and heating temperature (X3) signiﬁ-
cantly affected the absorbance (Y) of the CEF–ninhydrin
complex (P< 0.05). An interaction was observed between
the ninhydrin reagent concentration (X1) and the volume
of ninhydrin reagent (X2) (P= 0.078); an interaction was
also observed between the volume of ninhydrin reagent
(X2) and the heating temperature (X3) (P= 1.000) but it
was an insigniﬁcant one (P> 0.05). No interaction was
observed (P= 1.000) between the ninhydrin reagent concen-
tration (X1) and heating temperature (X3). An interaction
plot is shown in Fig. 4.
Response surface and contour plots were also analyzed to
visualize the effects of the parameters on the selected response
Y. Fig. 5 shows the effects of the ninhydrin reagent concentra-
tion (X1), volume of ninhydrin reagent (X2) and heating tem-
perature (X3) on the selected response Y. The contour plots
show non-linear effects of these factors on selected response
Y (Fig. 6). It may be interpreted from the surface diagram that
the ninhydrin reagent concentration (X1) is in the range of 0.2–
0.25% w/v and that a heating temperature (X3) in the range of
80–85 C gives the maximum absorbance (Y) (Fig. 6a).art of the effect.
Table 4 Analysis of variance for selected response.
Source DF Seq SS Adj SS Adj MS F P
Regression 9 0.003478 0.003478 0.000386 93.12 0.000
Linear 3 0.001362 0.001362 0.000454 109.13 0.000
Temp 1 0.000760 0.000760 0.000760 183.25 0.000
Vol 1 0.000496 0.000496 0.000496 119.55 0.000
Con 1 0.000105 0.000105 0.000105 25.33 0.004
Square 3 0.002096 0.002096 0.000699 168.37 0.000
Temp*Temp 1 0.000440 0.000612 0.000612 147.48 0.000
Vol*Vol 1 0.000161 0.000244 0.000244 58.73 0.001
Con*Con 1 0.001495 0.001495 0.001495 360.35 0.000
Interaction 3 0.000020 0.000020 0.000007 1.63 0.296
Temp*Vol 1 0.000000 0.000000 0.000000 0.00 1.000
Temp*Con 1 0.000000 0.000000 0.000000 0.00 1.000
Vol*Con 1 0.000020 0.000020 0.000020 4.88 0.078
Residual error 5 0.000021 0.000021 0.000004
Lack-of-Fit 3 0.000021 0.000021 0.000007 * *
Pure Error 2 0.000000 0.000000 0.000000
Total 14 0.003499
Table 5 Estimated regression coefﬁcient for selected response.
Term Coef. SE Coef T p
Constant 0.243000 0.001176 206.606 0.000
Temp 0.009750 0.000720 13.537 0.000
Vol 0.007875 0.000720 10.934 0.000
Con 0.003625 0.000720 5.0333 0.004
Temp*Temp 0.012875 0.001060 12.144 0.000
Vol*Vol 0.008125 0.001060 7.664 0.001
Con*Con 0.020125 0.001060 18.683 0.000
Temp*Vol 0.000000 0.001019 0.000 1.000
Temp*Con 0.000000 0.001019 0.000 1.000
Vol*Con 0.002250 0.001019 2.209 0.078
S = 0.00203715 PRESS = 0.000332.
R-Sq = 99.41%, R-Sq(Pred) = 90.51%, R-Sq(adj) = 98.34%.
S106 Y.B. Wani, D.D. PatilThe volume of ninhydrin reagent (X2) was in the range of
0.8–1.25 mL and a heating temperature (X3) in the range from
80 C to 85 C gives maximum absorbance (Y) (Fig. 6b).
The volume of ninhydrin reagent (X2) was in the range of
0.9–1.3 mL and a ninhydrin reagent concentration (X1) in
the range from 0.18% to 0.21% w/v gives the maximum absor-
bance (Y) (Fig. 6c).
4.3. Model validation
The experimental results and the predicted values obtained
using the polynomial model show that the predicted values
match the selected response Y reasonably with an R-Sq of
99.41% and an R-Sq (adj) of 98.34%.
Fig. 7 shows the residual plots of the selected response Y in
the model equation. The distribution of the residuals of the re-
sponse approximately follows the ﬁtted normal distribution,
whereas the residuals of the response are randomly scattered
in the residual plots.4.4. Reaction mechanism
Ninhydrin tautomerizes to 1,2,3-indantrione which forms
Schiff’s base with the amino acid. The ketimine formed under-goes decarboxylation yielding the aldehyde and an intermedi-
ate amine. Condensation of this intermediate amine with
another molecule of ninhydrin follows to form Ruheumann’s
purple product [32].
The reaction of CEF with ninhydrin is shown in Fig. 8.
Different experimental parameters such as the ninhydrin re-
agent concentration, amount of ninhydrin reagent, heating
temperature, heating time and diluting solvent were optimized
using an experimental design approach for the maximum
absorption value of the colored reaction mixture.4.5. Spectral characteristics
The scanning speed was optimized by scanning the solutions in
the low, medium and fast scanning modes. The medium scan-
ning speed was selected for the analysis from the UV–visible
absorption spectrum. The condensation product of CEF with
ninhydrin has the maximum absorption at 436 nm against
the colorless reagent blank.
4.6. Choice of solvent for preparation of CEF solution
Considering the volatility and cost of methanol, a methanol:
water mixture (3:2, v/v) was used for preparing the CEF
solution.
4.7. Choice of solvent for ninhydrin reagent solution
Ninhydrin undergoes more sensitive reactions in organic sol-
vents compared with solvent mixtures containing water [33].
Hence, methanol was selected as the solvent for preparing
the ninhydrin solution.
4.8. Diluting solvent
The ﬁnal dilution of the reaction mixture was done with water.
The ﬁnal dilution of the reaction mixture with water showed a
20% increase in absorption compared with dilution with a
methanol: water mixture (3:2 v/v).
Figure 4 Interaction plot of response Y.
Figure 5 Response surface plot of response Y (5a) X1: Ninhydrin reagent Conc. versus X3: Heating Temp. (5b) X2: Vol. of Ninhydrin
reagent versus X3: Heating Temp. (5c) X1: Ninhydrin reagent Conc. versus X2: Vol. of Ninhydrin reagent.
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A calibration graph of the CEF concentration versus the
absorbance was constructed for the method under optimum
conditions as described above. A linear relationship was
found in the concentration range of 5–30 lg/mL. The graph
shows a good correlation coefﬁcient (r2 = 0.9995) with the
intercept (0.001) calculated by using the regression equation
(Table 6).
4.10. Assay results of CEF in pharmaceutical formulation
The results obtained from the analysis of marketed formulations
are provided in Table 7. The percent purities of the marketed for-mulations, namelyHIFENDT100 tablet andZIFIDT50 tab-
letwere found tobe 99.60 ± 0.37 and 100.53 ± 0.50, respectively.
4.11. Accuracy
The accuracy of the proposed method was determined through
a recovery study [34]. A known amount of pure CEF was used
to spike to pre-analyzed tablet formulation. Analysis of CEF
was carried out at three concentration levels (80%, 100%
and 120%) within the speciﬁed linearity range. Determination
of the CEF content was carried out using the formula men-
tioned in the section titled ‘‘Assay of CEF in pharmaceutical
formulations’’. The percent recovery of the proposed method
was calculated using the formula as below.
Figure 6 Contour plots of response Y (6a) X3: Heating Temp. versus X1: Ninhydrin reagent Conc. (6b) X3: Heating Temp. versus X2:
Vol. of Ninhydrin reagent (6c) X2: Vol. of Ninhydrin reagent versus X1: Ninhydrin reagent Conc.
Figure 7 Residual plots of response Y.
Figure 8 Reaction of CEF with ninhydrin.
Table 6 Optical characteristics and statistical data of the
regression equations for the drug reaction with ninhydrin.
Parameter CEF-Ninhydrin
pH Alkaline borate buﬀer pH 10
Color Yellow
kmax (nm) 436
Beer–Lambert’s law limit (lg/ml) 5–30
Molar absorptivity (L/mol cm) 2.13 · 104




S108 Y.B. Wani, D.D. Patil% recovery ¼ E
Tþ P 100
where, E = total amount of CEF estimated (mg); T = amount
of CEF from pre-analysis of the tablet powder (mg); and
P = amount of pure CEF added (mg).
The average percent recoveries for HIFEN DT 100 tablet
and ZIFI DT 50 tablet are found to be 102.02 ± 0.61 and
100.64 ± 0.71, respectively (Table 8).4.12. Precision
The inter-day precision and intra-day precision of the method
were determined. A repeatability study (Intra-day precision)
was performed by analyzing a sample of CEF repeatedly with-
in a day. An inter-day precision study was performed by ana-
Table 7 Determination of CEF in Pharmaceutical formulation.
Label Claim Amount of drug found in mg, ±%RSD (n= 5)
Proposed method Reported method t-Valuea F-valueb
HIFEN DT 100 Tablet 99.60 ± 0.37 100.43 ± 0.31 1.7757 0.7275
ZIFI DT 50 Tablet 100.53 ± 0.50 100.99 ± 0.62 1.2818 0.6288
a t0.05%, 4 = 2.776.
b F0.05%, 4 = 6.39.
Table 8 Results of recovery studies by the standard addition method.
Amount of drug in tablet mg Amount of pure drug spiked, mg Total found, mg Recovery of pure drug added% %RSD (n= 3)
HIFEN DT 100 Tablet
10 8 18.45 102.50 0.60
10 10 20.50 102.48 0.44
10 12 22.24 101.09 0.80
Mean 102.02 0.61
ZIFI DT 50 Tablet
10 8 90.29 101.67 1.49
10 10 99.65 100.12 0.38
10 12 109.45 100.15 0.27
Mean 100.64 0.71
Figure 9 Stoichiometry of CEF–Ninhydrin complex.
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sults of inter-day precision and intra-day precision were ex-
pressed as %RSD and they were found to be 0.92 and 1.12,
respectively. The %RSD value indicates that the method has
good precision.
4.13. Limit of detection and limit of quantitation
The limit of detection (LOD) and limit of quantitation (LOQ)
of the analytical method developed for estimating the CEF
content were calculated using the following formulae.
LOD ¼ ð3:3 rÞ=S
LOQ ¼ ð10 rÞ=S
where, r= standard deviation of the response; and S = slope
of calibration curve.
The limit of detection and limit of quantitation were found
to be 1.4045 and 4.2136 lg/mL, respectively.
4.14. Speciﬁcity study
A speciﬁcity study was performed under different stress condi-
tions. Drug samples were exposed to 0.1 M HCl (1 mL), 0.1 N
NaOH (1 mL), 3%H2O2 (1 mL), thermal (50 C) and UV radi-
ations for 24 h. After 24 h, the samples were analyzed according
to the procedure described in the section titled ‘‘Assay of CEF in
pharmaceutical formulations’’. The results of the speciﬁcity
study show that the proposed method is a speciﬁc one.
4.15. Stability of solution
The solution used in the precision study was stored for 24 h at
room temperature. During the storage period, the absorbance
of the solution was measured after different time intervals (0,15, 30 min, 1, 2, 3, 4, 5, 6 and 24 h), and it was found that
the color intensity of the solution was stable up to 6 h.
4.16. Stoichiometry of the complex
The ratio of CEF and ninhydrin in the complex was deter-
mined using the molar ratio method [20]. Satisfactory color
development occurred with a ninhydrin to CEF molar ratio
of 20:1, but molar ratios as high as 100:1 did not adversely af-
fect the reaction (Fig. 9). A molar ratio of 10:1 was insufﬁcient
for maximum color development. Possible reasons for non-
ideal stoichiometry in the formation of diketohydrindylidene-
diketohydrindamine between ninhydrin and CEF are slow for-
mation, side reaction, hydrolytic, oxidative, photolytic insta-
bility and interfering color [12].
S110 Y.B. Wani, D.D. Patil4.17. Statistical analysis of the results
The validity of the proposed method for determining the CEF
content in pharmaceutical formulations was tested by analyz-
ing the CEF using a previously described HPLC method
[26]. The results of the statistical comparison are given in Ta-
ble 7. At the 95% conﬁdence level, the calculated t-value and
F-value do not exceed the theoretical values for either HIFEN
DT 100 tablet or ZIFI DT 50 tablet. Therefore, there is no
signiﬁcant difference between the proposed and reported meth-
ods, indicating that the proposed method is as accurate and
precise as the reported method [35].
5. Conclusions
A two-level full factorial design was used to design an experi-
mental program to provide data regarding inﬂuencing factors
that had signiﬁcant effects on the selected response. One-way
ANOVA and Pareto ranking analyses showed that the ninhy-
drin reagent concentration (X1), volume of ninhydrin reagent
(X2) and heating temperature (X3) were statistically signiﬁcant
factors (P< 0.05) affecting the formation of the ceﬁxime–nin-
hydrin complex Y (absorbance). A Box-Behnken experimental
design with response surface methodology was then utilized to
evaluate the main, interaction and quadratic effects of these
three factors on the selected response Y. With the help of a re-
sponse surface plot and contour plot, the optimum values of
the selected factors were identiﬁed. The predicted values of
the response matched the experimental values reasonably well,
with an R-Sq of 99.41% and an R-Sq (adj) of 98.34% for the
selected response Y. In order to gain a better understanding of
the effects of the variables on the selected response Y, the pre-
dicted model was presented in the form of a response surface
and contour plot design. It was concluded that the experimen-
tal design concept could be effectively used to optimize a spec-
trophotometric method for estimating the ceﬁxime trihydrate
content in bulk and pharmaceutical formulations with the least
number of experimental runs possible.Acknowledgments
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